Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual ...
October 18 2019 - 8:30AM
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company
focused on the development of intravenous (“IV”) tramadol for the
U.S. market, today announced an eAbstract presentation at
ANESTHESIOLOGY® 2019, the Annual Meeting of the American Society of
Anesthesiologists in Orlando, FL from October 19-23, 2019.
The eAbstract (A2170) entitled “Tramadol
Hydrochloride Injection: Effective Relief of Postsurgical Pain in
Patients Undergoing Bunionectomy Surgery”, is scheduled to be
presented on Sunday, October 20th at 10:45 a.m. EDT. The eAbstract
will highlight the Phase 3 data for IV tramadol in the management
of post-surgical pain in patients undergoing bunionectomy, an
orthopedic model.
“Patients are often treated with Schedule II
narcotics due to a lack of other options,” said David Leiman, M.D.,
Director, HD Research Corp. and Clinical Assistant Professor of
Surgery at The University of Texas at Houston, an investigator in
IV tramadol's Phase 3 program. “These data suggest that IV
tramadol, if approved, may become an important new therapy for
managing postoperative pain and offer a potential alternative that
could reduce the use of Schedule II narcotics.”
This Phase 3, multicenter, double-blind,
placebo-controlled trial evaluated the efficacy and safety of IV
tramadol in 409 patients following bunionectomy surgery. Patients
were randomized in a 1:1:1 ratio to a postoperative regimen of 50
mg of IV tramadol, 25 mg of IV tramadol or placebo administered
over 15 minutes at hours 0, 2, 4 and once every 4 hours thereafter,
for up to 13 doses. The primary endpoint of the bunionectomy study
assessed the analgesic efficacy of IV tramadol compared to placebo
as measured by SPID48. The key secondary endpoints included SPID24,
total consumption of rescue medicine and Patient Global Assessment,
which captures the patient’s perception of the treatment. As
previously announced, IV tramadol 50 mg met the primary as well as
all of the key secondary endpoints.
About Avenue TherapeuticsAvenue
is a specialty pharmaceutical company focused on the development
and commercialization of intravenous (IV) tramadol for the
management of moderate to moderately severe postoperative pain. IV
tramadol may fill a gap in the acute pain market between IV
acetaminophen/NSAIDs and IV conventional narcotics. Avenue has
completed its Phase 3 program of IV tramadol for the management of
postoperative pain and plans to submit a New Drug Application to
the U.S. Food and Drug Administration by year-end. Avenue is
headquartered in New York City and was founded by Fortress Biotech,
Inc. (NASDAQ: FBIO). For more information, visit
www.avenuetx.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth
strategy; risks relating to the results of research and development
activities; risks relating to the timing of starting and completing
clinical trials; our ability to obtain, perform under and maintain
financing and strategic agreements and relationships; uncertainties
relating to preclinical and clinical testing; our dependence on
third-party suppliers; our ability to attract, integrate and retain
key personnel; the early stage of products under development; our
need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as
other risks described in our SEC filings. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions or circumstances on which any such statement is based,
except as required by law.
Contacts: Jaclyn Jaffe and William BegienAvenue
Therapeutics, Inc. (781) 652-4500ir@avenuetx.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024